Safety and Efficacy of First-Line Dacomitinib in Advanced Non-Small Cell Lung Cancer by EGFR Mutation SUBtype in ARCHER 1050

被引：0

作者：

Pluzanski, A. ^{[1
]}

Wu, Y. ^{[2
,3
]}

Cheng, Y. ^{[4
]}

Zhou, X. ^{[5
]}

Migliorino, M. R. ^{[6
]}

Niho, S. ^{[7
]}

Nakagawa, K. ^{[8
]}

Lee, K. H. ^{[9
]}

Corral, J. ^{[10
]}

Rosell, R. ^{[11
]}

Linke, R. ^{[12
]}

Tang, Y. ^{[13
]}

Pastel, M. ^{[14
]}

Wilner, K. ^{[13
]}

Mok, T. ^{[15
]}

机构：

[1] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[2] Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China

[3] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China

[4] Jilin Prov Canc Hosp, Jilin, Jilin, Peoples R China

[5] Army Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China

[6] San Camillo Forlanini Hosp, Pulm Oncol Unit, Rome, Italy

[7] Natl Canc Ctr Hosp East Japan, Kashiwa, Chiba, Japan

[8] Kindai Univ Hosp, Osaka, Japan

[9] Chungbuk Natl Univ, Coll Med, Chungbuk Natl Univ Hosp, Cheongju, South Korea

[10] Hosp Univ Virgen Del Rocio, Seville, Spain

[11] Catalan Inst Oncol, Barcelona, Spain

[12] Sfj Pharmaceut, Pleasanton, CA USA

[13] Pfizer Oncol, La Jolla, CA USA

[14] Pfizer Oncol, New York, NY USA

[15] Chinese Univ Hong Kong, Dept Clin Oncol, State Key Lab Translat Oncol, Hong Kong, Peoples R China

来源：

关键词：

dacomitinib; non-small cell lung cancer; EGFR mutation;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P76.67

引用

页码：S617 / S618

页数：2